Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03253263 · ClinicalTrials.gov registry record · Phase 2
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
A Phase 2 study of Bronchopulmonary Dysplasia and Intraventricular Hemorrhage, sponsored by OHB Neonatology.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 338
- Enrollment target
- 20
- Study locations
NCT03253263: Recruiting Phase 2 study of Bronchopulmonary Dysplasia and Intraventricular Hemorrhage, sponsored by OHB Neonatology.
NCT03253263 is a Phase 2 study of Bronchopulmonary Dysplasia and Intraventricular Hemorrhage that is actively recruiting participants, run by OHB Neonatology. The registered enrollment target is 338 participants, above the 225-participant average among 29 other Bronchopulmonary Dysplasia trials with a reported enrollment target (50% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03253263, a Phase 2 study of Bronchopulmonary Dysplasia and Intraventricular Hemorrhage, is actively recruiting participants, sponsored by OHB Neonatology.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 338 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.
Primary Outcome
Severe BPD is defined by the modified NICHD severity grading
Conditions Studied
Interventions
- DRUG OHB-607
Study Locations (20)
Arkansas
- Arkansas Children's Hospital - Little Rock
- University of Arkansas for Medical Sciences - Little Rock
California
- Children's Hospital of Orange County - California City
- LAC USC Medical Center - Los Angeles
Florida
- Jackson Memorial Hospital - Miami
- Tampa General Hospital - Tampa
Indiana
- Riley Hospital for Children - Indianapolis
- Memorial Hospital of South Bend - South Bend
Massachusetts
- Tufts Medical Center - Boston
- Boston Children's Hospital - Boston
Minnesota
- Children's Minnesota - Children's Hospital and Clinics - St. Paul - Saint Paul
- Children's Minnesota - Children's Hospital and Clinics - Saint Paul
New York
- University of Rochester - Rochester
- Maria Fareri Children's Hospital - Valhalla
Illinois
- University of Illinois at Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2019-05-09 |
| Est. Completion | 2028-01-21 |
| Phase | Phase 2 |
What NCT03253263 shows while recruiting
NCT03253263 is an interventional study that assigns participants to a tested intervention. The registered 338 participants enrollment target is mid-sized for trials with a published cap, above the 225-participant average among 29 other Bronchopulmonary Dysplasia trials with a reported enrollment target (50% higher).
The record links to 4 conditions, with Bronchopulmonary Dysplasia appearing as the primary indexed condition, and to 1 intervention - of which OHB-607 is the first listed.
NCT03253263 names 20 study sites across 13 states, led by Arkansas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT03253263 about?
NCT03253263 is a clinical study titled "A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants". The purpose of this study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.
What is the current status of trial NCT03253263?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 338 participants. The study started on 2019-05-09. Estimated completion is 2028-01-21.
What conditions does trial NCT03253263 study?
This clinical trial studies the following conditions: Bronchopulmonary Dysplasia, Intraventricular Hemorrhage, Retinopathy of Prematurity (ROP), Chronic Lung Disease of Prematurity.
What interventions are being tested in trial NCT03253263?
The interventions under investigation include: OHB-607 (DRUG).
Who is sponsoring clinical trial NCT03253263?
This trial is sponsored by OHB Neonatology, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03253263 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bronchopulmonary Dysplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03253263's enrollment target sits among peer trials
338 8th of 29 higher than 22 of 29 other Bronchopulmonary Dysplasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bronchopulmonary Dysplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Vitamin D Supplementation for Extremely Preterm Infants
COMPLETED · Phase 2
-
Safety of Sildenafil in Premature Infants
COMPLETED · Phase 2
-
Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)
COMPLETED · Phase 2
-
Trial II of Lung Protection With Azithromycin in the Preterm Infant
COMPLETED · Phase 2
-
Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome
COMPLETED · Phase 2
-
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05658731 · 338 participants · NA
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
- NCT06022939 · 338 participants · Phase 3
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
- NCT04545424 · 340 participants · Phase 2
Trial of Therapeutic Hypothermia in Patients With ARDS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI